Assessing individual bioequivalence with high-order cross-over designs: A unified procedure

Statistics in Medicine

Volumn 22, Issue 18, 2003, Pages 2847-2860

  Hsuan, Francis C ^a   Reeve, Russell ^b  

^a TEMPLE UNIVERSITY   (United States)

^b NONE

Author keywords

High order cross over design; Howe's confidence interval; Individual bioequivalence; Multivariate model

Indexed keywords

VERAPAMIL;

ANALYSIS OF VARIANCE; ANALYTIC METHOD; ARTICLE; BIOEQUIVALENCE; BIOSTATISTICS; COMPUTER SIMULATION; CROSSOVER PROCEDURE; DRUG DOSAGE FORM; DRUG FORMULATION; EXPERIMENTAL DESIGN; FOOD AND DRUG ADMINISTRATION; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MULTIVARIATE ANALYSIS; STATISTICAL MODEL;

ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; HUMANS; LINEAR MODELS; MULTIVARIATE ANALYSIS; RESEARCH DESIGN; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VERAPAMIL;

EID: 0141737472     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1382     Document Type: Article

References (19)

1. FDA Guidance for Industry. Statistical approaches to establishing bioequivalence. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, posted January 2001.
2. Anderson S, Hauck WW. Considerations of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 1990; 18:259-273.
3. Chow S, Liu JP. Design and Analysis of Bioequivalence Studies. Marcel Dekker: New York, 1992.
4. Hyslop T, Hsuan F, Holder D. A small sample confidence interval approach to assess individual bioequivalence. Statistics in Medicine 2000; 19:2885-2897.
5. Shao J, Chow SC, Wang H. Individual bioequivalence testing under 2 × 3 designs. Statistics in Medicine 2002; 21:629-648.
6. Hyslop T, Iglewicz, B. Alternative cross-over designs for individual bioequivalence. In 2001 Proceedings of the American Statistical Association. Biopharmaceutical Section [CD-ROM], American Statistical Association: Alexandria, VA, 2001.
7. Endrenyi L, Taback N, Tothfalusi L. Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence. Statistics in Medicine 2000; 19:2867-2878.
8. Searle SR, Casella G, McCulloch CE. Variance Components. Wiley: New York, 1992; 137.
9. Sheiner L. Bioequivalence revisited. Statistics in Medicine 1992; 11:1777-1788.
10. Schall R, Luus HE. On population and individual bioequivalence. Statistics in Medicine 1993; 12:1109-1124.
11. Chen ML, Patnaik R, Hauck WW, Schuirmann DJ, Hyslop T, Williams R. An individual bioequivalence criterion: regulatory considerations. Statistics in Medicine 2000; 19:2821-2842.
12. Howe WG. Approximate confidence limits on the mean of X+Y where X and Y are two tabled independent random variables. Journal of the American Statistical Association 1974; 69:789-794.
13. Hampel FR. The robustness of some nonparametric procedures. In A Festschrift for Erich L. Lehmann: in Honor of his Sixty-Fifth Birthday, Bickel PJ, Doksum KA, Hodges JL Jr. (eds). Statistics/Probability Series. Wadsworth: Belmont (CA), 1983.
14. Chinchilli V. The assessment of individual and population bioequivalence. Journal of Biopharmaceutical Statistics 1996; 6(1):1-14.
15. Jones B, Kenward MG. Design and Analysis of Crossover Trials. Chapman & Hall: London, 1989.
16. Chinchilli VM, Esinhart JD. Design and analysis of intra-subject variability in cross-over experiments. Statistics in Medicine 1996; 15:1619-1634.
17. Kimanani EK, Lavigne J, Potvin D. Numerical methods for the evaluation of individual bioequivalence criteria. Statistics in Medicine 2000; 19:2775-2795.
18. McCullagh P, Nelder JA. Generalized Linear Models. 2nd edn. Chapman & Hall: London, 1989.
19. Ting N, Wang W, Wei G. Population bioequivalence. In Encyclopedia of Biopharmaceutical Statistics, Chow SC (ed.). Marcel Dekker: New York (to appear).